Development and characterization of a new model of tacrine-induced hepatotoxicity: Role of the sympathetic nervous system and hypoxia- reoxygenation

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 3, 1997, Pages 1591-1599

  Stachlewitz, Robert F ^a   Arteel, Gavin E ^b   Raleigh, James A ^a,b   Connor, Henry D ^c   Mason, Ronald P ^c   Thurman, Ronald G ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TACRINE;

ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DRUG EFFECT; ELECTRON SPIN RESONANCE; FEMALE; INTRAGASTRIC DRUG ADMINISTRATION; LIVER ISCHEMIA; LIVER TOXICITY; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; SYMPATHETIC INNERVATION; TOXICITY TESTING;

ANIMALS; BODY TEMPERATURE REGULATION; CELL HYPOXIA; CHOLINESTERASE INHIBITORS; DENERVATION; FEMALE; FREE RADICALS; LIVER; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; SYMPATHETIC NERVOUS SYSTEM; TACRINE;

EID: 0030930866     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. AMES, D. J., BHATHAL, P. S., DAVIES, B. M., FRASER, J. R. E., GIBSON, P. R. AND ROBERTS, S.: Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine. Aust. N.Z. J. Med. 20: 193-195, 1990.
2. ARTEEL, G. E., THURMAN, R. G., YATES, J. A. AND RALEIGH, J. A.: Evidence that hypoxia markers detect oxygen gradients in liver: Pimonidazole and retrograde perfusion of rat liver. Br. J. Cancer 72: 889-895, 1995.
3. ARTEEL, G. E., RALEIGH, J. A., BRADFORD, B. U. AND THURMAN, R. G.: Acute alcohol produces hypoxia directly in rat liver in vivo: Role of Kupffer cells. Am. J. Physiol. 271: G494-G500, 1996.
4. BECKH, K., OTTO, R., J. I., S. AND JUNGERMANN, K.: Control of oxygen uptake, microcirculation and glucose release by circulating noradrenaline in the perfused rat liver. Biol. Chem. 366: 671-678, 1985.
5. BELINSKY, S. A., POPP, J. A., KAUFFMAN, F. C. AND THURMAN, R. G.: Trypan blue uptake as a new method to investigate hepatotoxicity in periportal and pericentral regions of the liver lobule: Studies with allyl alcohol in the perfused liver. J. Pharmacol. Exp. Ther. 230: 755-760, 1984.
6. BERGMEYER, H. U.: Methods of Enzymatic Analysis, Academic Press, New York, 1983.
7. BRODY, T. M., CALVERT, D. N. AND SCHNEIDER, A. F.: Alteration of carbon tetrachloride-induced pathologic changes in the rat by spinal transection, adrenalectomy and adrenergic blocking agents. J. Pharmacol. 131: 341-345, 1961.
8. 4 toxicity. Am. J. Physiol. 198: 669-676, 1960.
9. CUCCHIARO, G., YAMAGUCHI, Y., MILLS, E., KUHN, C. M., ANTHONY, D. C., BRANUM, G. D., EPSTEIN, R. AND MEYERS, W. C.: Evaluation of selective liver denervation methods. Am. J. Physiol. 259: G781-G785, 1990.
10. ELINDER, F., MOHAMMED, A. K., WINBLAD, B. AND ARHEM, P.: Effects of THA on ionic currents in myelinated axons of Xenopus laevis. Eur. J. Pharmacol. 164: 599-602, 1989.
11. FARLOW, M., GRACON, S. I., HERSHEY, L. A., LEWIS, K. W., SADOWSKY, C. H. AND DOLAN-URENO, J.: A controlled trial of tacrine in Alzheimer's disease. JAMA 268: 2523-2529, 1992.
12. FITTEN, L. J., FLOOD, J. F., BAXTER, C. F., TACHIKI, K. H. AND PERRYMAN, K.: Long-term oral administration of memory-enhancing doses of tacrine in mice: A study of potential toxicity and side effects. J. Gerontol .42: 681-685, 1987.
13. FORD, J. M., TRUMAN, C. A., WILCOCK, G. K. AND ROBERTS, C. J. C.: Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin. Pharmacol. Ther. 53: 691-695, 1993.
14. FORSYTH, D. R., SURMON, D. J., MORGAN, R. A. AND WILCOCK, G. K.: Clinical evidence with and side-effects of tacrine hydrochloride in Alzheimer's disease: A pilot study. Age Ageing 18: 223-229, 1989a.
15. FORSYTH, D. R., WILCOCK, G. K., MORGAN, R. A., TRUMAN, C. A., FORD, J. M. AND ROBERTS, C. J. C.: Pharmacokinetics of tacrine hydorchloride in Alzheimer's disease. Clin. Pharmacol. Ther. 46: 634-641, 1989b.
16. GAMZU, E. R., THAL, L. J. AND DAVIS, K. L.: Therapeutic trials using tacrine and other cholinesterase inhibitors. Adv. Neurol. 51: 241-244, 1990.
17. GARDEMANN, A., PUSCHEL, G. P. AND JUNGERMANN, K.: Nervous control of liver metabolism and hemodynamics. Eur. J. Biochem. 207: 399-411, 1992.
18. HAMMEL, P., LARREY, D., BERNUAU, J., KALAFAT, M., FRENEAUX, E., BABANY, G., DEGOTT, C., FELDMANN, G., PASSAYRE, D. AND BENHAMOU, J.: Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease. J. Clin. Gastroenterol. 12: 329-331, 1990.
19. HSU, R. S., DILEO, E. M. AND CHESSON, S. M.: High-performance liquid chromatography for the determination of tacrine and its metabolites in plasma. J. Chromatog. 530: 170-176, 1990.
20. HUNTER, A. J., MURRAY, T. K., JONES, J. A., CROSS, A. J. AND GREEN, A. R.: The cholinergic pharmacology of tetrahydroaminoacridine in vivo and in vitro. Br. J. Pharmacol. 98: 79-86. 1989.
21. JI, S., BECKH, K. AND JUNGERMANN, K.: Regulation of oxygen consumption and microcirculation by alpha-sympathetic nerves in isolated, perfused rat liver. FEBS Lett. 167: 117-122, 1984.
22. JONES, S. M. AND THURMAN, R. G.: L-arginine minimizes reperfusion injury in a low-flow, reflow model of liver perfusion. Hepatology 24: 163-168, 1996.
23. KNECHT, K. T., BRADFORD, B. U., MASON, R. P. AND THURMAN, R. G.: In vivo formation of a free radical metabolite of ethanol. Mol. Pharmacol. 38: 26-30, 1990.
24. KOOKA, N., CLEMONS, G. K. AND LOMAX, P.: Relationship between the temperature and endocrine changes induced by cholinesterase inhibitors. Pharmacology 34: 74-79, 1987.
25. LARSON, R. E.; PLAA, G. L. AND CREWS, L. M.: The effect of spinal cord transection on carbon tetrachloride hepatotoxicity. Toxicol. Appl. Pharmacol. 6: 154-162, 1964.
26. LARSON, R. E. AND PLAA, G. L.: A correlation of the effects of cervical cordotomy, hypothermia, and catecholamines on carbon tetrachloride-induced hepatic necrosis. J. Pharmacol. 147: 103-111, 1965.
27. LAUTT, W. W.: Hepatic nerves: a review of their functions and effects. Can. J. Physiol. 58: 105-123, 1980.
28. LEMASTERS, J. J., JI, S. AND THURMAN, R. G.: Centrilobular injury following hypoxia in isolated, perfused rat liver. Science 213: 661-663, 1981.
29. LEMASTERS, J. J. AND THURMAN, R. G.: Hypoxia and reperfusion injury to liver. In Progress in Liver Diseases, ed. by J. L. Boyer and R. K. Ockner, pp. 85-114, Saunders, Philadelphia, 1993.
30. MADDEN, S., WOOLF, T. F., POOL, W. F. AND PARK, B. K.: An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Biochem. Pharmacol. 46: 13-20, 1993.
31. MARX, J. L.: Alzheimer's drug put on hold. Science 238: 1041-1042, 1987.
32. O'BRIEN, J. T., EAGGER, S. AND LEVY, R.: Effects of tetrahydroaminoacridine on liver function in patients with Alzheimer's disease. Age Ageing 20: 129-131, 1991.
33. OWENS, N. J.: Focus on tacrine HCl. Hosp. Formul. 28: 679-691, 1993.
34. RALEIGH, J. A. AND KOCH, C. J.: Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharmacol. 40: 2457-2464, 1990.
35. SCHOLZ, R., HANSEN, W. AND THURMAN, R. G.: Inhibition of mixed-function oxidation with biosynthetic processes. Eur. J. Biochem. 38: 64-72, 1973.
36. SMITHEN, C. E. AND HARDY, C. R.: The chemistry of nitroimidazole hypoxic cell radiosensitizers. In Advanced Topics on Radiosensitizers of Hypoxic Cells, ed. by A. Breccia, C. Rimondi and G. E. Adams, pp. 1-47, Plenum Press, New York, 1982.
37. STACHLEWITZ, R. F. AND THURMAN, R. G.: Development and characterization of an acute model of tacrine hepatotoxicity (Abstract). Fund. Appl. Toxicol. 30: 79, 1996.
38. STARR, C.: Alzheimer's drug research. Where is it headed? Drug Topics 14: 32-42, 1992.
39. SUMMERS, W. K., VIESSELMAN, J. O., MARSH, G. M. AND CANDELORA, K: Use of THA in treatment of Alzheimer-like dementia: Pilot study in twelve patients. Biol. Psychiat. 16: 145-153, 1981.
40. SUMMERS, W. K., KOEHLER, A. L., MARSH, G. M., TACHIKI, K. AND KLING, A.: Long-term hepatotoxicity of tacrine. Lancet 2: 729, 1989.
41. TAYLOR, P.: Anticholinesterase agents. In The Pharmacological Basis of Therapeutics, ed. by A. Gilman, T. W. Rall, A. S. Nies and P. Taylor, pp. 131-149. Pergamon Press, Elmsford, 1990.
42. VOLGER, B. W.: Alternatives in the treatment of memory loss in patients with Alzheimer's disease. Clin Pharm 10: 447-456, 1991.
43. WAKTKINS, P. B., ZIMMERMAN, H. J., KNAPP, M. J., GRACON, S. I. AND LEWIS, K. W.: Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA 271: 992-998, 1994.
44. WOOLF, T. F., POOL, W. F., BJORGE, S. M., CHANG, T., GOEL, O. P., PURCHASE, C. F., SCHOEDER, M. C., KUZE, K. L. AND TRAGER, W. F.: Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Drug Metab. Disposit. 21: 874-882, 1993.
45. W. U., C. C. AND YANG, J. T.: Tacrine protection of acetylcholinesterase from activation by diisopropylfluorophosphate: A circular dichroism study. Mol. Pharmacol. 35: 85-92, 1989.
46. ZHONG, Z., JONES, S. J. AND THURMAN, R. G.: Glycine minimizes reperfusion injury in a low-flow, reflow liver perfusion model in the rat. Am. J. Physiol. 270: G332-G338, 1996.